Trial · NCT03390504
Results by group348
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 348
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival (OS) | Cohort 1: Arm 1A: Erdafitinib 8 mg/9 mg | 12.06 | 95% Confidence Interval 10.25 to 16.36 | Months | |
| Overall Survival (OS) | Cohort 1: Arm 1B: Chemotherapy (Vinflunine 320 mg/m^2 or Docetaxel 75 mg/m^2) | 8.74 | 95% Confidence Interval 6.67 to 10.71 | Months | |
| Overall Survival (OS) | Cohort 2: Arm 2A: Erdafitinib 8 mg/ 9 mg | 10.91 | 95% Confidence Interval 9.23 to 12.58 | Months | |
| Overall Survival (OS) | Cohort 2: Arm 2B: Pembrolizumab 200 mg | 11.07 | 95% Confidence Interval 9.72 to 13.63 | Months | |
| Progression Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 | Cohort 1: Arm 1A: Erdafitinib 8 mg/9 mg | 5.39 | 95% Confidence Interval 4.37 to 5.62 | Months | |
| Progression Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 | Cohort 1: Arm 1B: Chemotherapy (Vinflunine 320 mg/m^2 or Docetaxel 75 mg/m^2) | 2.73 | 95% Confidence Interval 2.10 to 4.17 | Months | |
| Progression Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 | Cohort 2: Arm 2A: Erdafitinib 8 mg/ 9 mg | 4.44 | 95% Confidence Interval 4.07 to 5.49 | Months | |
| Progression Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 | Cohort 2: Arm 2B: Pembrolizumab 200 mg | 2.69 | 95% Confidence Interval 1.64 to 3.02 | Months | |
| Objective Response Rate (ORR) Per RECIST Version 1.1 | Cohort 1: Arm 1A: Erdafitinib 8 mg/9 mg | 46.9 | Percentage of participants | ||
| Objective Response Rate (ORR) Per RECIST Version 1.1 | Cohort 1: Arm 1B: Chemotherapy (Vinflunine 320 mg/m^2 or Docetaxel 75 mg/m^2) | 12.6 | Percentage of participants | ||
| Objective Response Rate (ORR) Per RECIST Version 1.1 | Cohort 2: Arm 2A: Erdafitinib 8 mg/ 9 mg | 40.0 | Percentage of participants | ||
| Objective Response Rate (ORR) Per RECIST Version 1.1 | Cohort 2: Arm 2B: Pembrolizumab 200 mg | 21.6 | Percentage of participants | ||
| Change From Baseline in Physical Functioning Scales of the Functional Assessment of Cancer Therapy - Bladder Cancer (FACT-Bl) | Cohort 1: Arm 1A: Erdafitinib 8 mg/9 mg | -3.70 | Standard Error 2.365 | Score on scale | |
| Change From Baseline in Physical Functioning Scales of the Functional Assessment of Cancer Therapy - Bladder Cancer (FACT-Bl) | Cohort 1: Arm 1B: Chemotherapy (Vinflunine 320 mg/m^2 or Docetaxel 75 mg/m^2) | -5.28 | Standard Error 2.746 | Score on scale | |
| Change From Baseline in Physical Functioning Scales of the Functional Assessment of Cancer Therapy - Bladder Cancer (FACT-Bl) | Cohort 2: Arm 2A: Erdafitinib 8 mg/ 9 mg | -4.56 | Standard Error 1.946 | Score on scale | |
| Change From Baseline in Physical Functioning Scales of the Functional Assessment of Cancer Therapy - Bladder Cancer (FACT-Bl) | Cohort 2: Arm 2B: Pembrolizumab 200 mg | -0.26 | Standard Error 1.980 | Score on scale | |
| Time Until Symptom Deterioration | Cohort 1: Arm 1A: Erdafitinib 8 mg/9 mg | 1.5 | 95% Confidence Interval 0.82 to 2.83 | Months | |
| Time Until Symptom Deterioration | Cohort 1: Arm 1B: Chemotherapy (Vinflunine 320 mg/m^2 or Docetaxel 75 mg/m^2) | 2.8 | 95% Confidence Interval 1.51 to 5.32 | Months | |
| Time Until Symptom Deterioration | Cohort 2: Arm 2A: Erdafitinib 8 mg/ 9 mg | 2.1 | 95% Confidence Interval 1.41 to 3.48 | Months | |
| Time Until Symptom Deterioration | Cohort 2: Arm 2B: Pembrolizumab 200 mg | 2.1 | 95% Confidence Interval 1.38 to 4.17 | Months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03390504/results